{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:38:41Z","timestamp":1787855921406,"version":"build-2784847793"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81270769"],"award-info":[{"award-number":["81270769"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000703"],"award-info":[{"award-number":["82000703"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20211054"],"award-info":[{"award-number":["BK20211054"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010854","name":"Jiangsu Provincial Commission of Health and Family Planning","doi-asserted-by":"publisher","award":["2016103003"],"award-info":[{"award-number":["2016103003"]}],"id":[{"id":"10.13039\/501100010854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010854","name":"Jiangsu Provincial Commission of Health and Family Planning","doi-asserted-by":"publisher","award":["H201628"],"award-info":[{"award-number":["H201628"]}],"id":[{"id":"10.13039\/501100010854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejphar.2022.175053","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T20:45:20Z","timestamp":1655153120000},"page":"175053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Effect of Sacubitril\/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study"],"prefix":"10.1016","volume":"928","author":[{"given":"Ruoyu","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luhua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4546-404X","authenticated-orcid":false,"given":"Dong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.175053_bib1","doi-asserted-by":"crossref","first-page":"F24","DOI":"10.1152\/ajprenal.00347.2010","article-title":"Transient and sustained increases in glomerular permeability following ANP infusion in rats","volume":"300","author":"Axelsson","year":"2011","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2022.175053_bib2","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1523-1755.2004.00982.x","article-title":"Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy","volume":"66","author":"Benigni","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2022.175053_bib3","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.jacc.2011.07.020","article-title":"Cardiac resynchronization therapy reduces left atrial volume and the risk of atrial tachyarrhythmias in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)","volume":"58","author":"Brenyo","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2022.175053_bib4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1046\/j.1523-1755.1998.00895.x","article-title":"C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo","volume":"53","author":"Canaan-Kuhl","year":"1998","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2022.175053_bib5","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/01.hjh.0000179765.48324.b4","article-title":"Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats","volume":"23","author":"Cheng","year":"2005","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2022.175053_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cardfail.2010.10.005","article-title":"Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure","volume":"17","author":"Chow","year":"2011","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ejphar.2022.175053_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.175053_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejphar.2022.175053_bib9","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jacc.2014.01.087","article-title":"Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment","volume":"64","author":"Damman","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2022.175053_bib10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2022.175053_bib11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.pcad.2011.01.003","article-title":"The cardiorenal syndrome in heart failure","volume":"54","author":"Damman","year":"2011","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.ejphar.2022.175053_bib12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.2932797","article-title":"Atrial natriuretic factor: a hormone produced by the heart","volume":"230","author":"de Bold","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2022.175053_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2010.531","article-title":"Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts","volume":"80","author":"Gansevoort","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2022.175053_bib14","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.175053_bib15","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of Sacubitril\/Valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2022.175053_bib16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/ndt\/gfz058","article-title":"Chronic kidney disease, heart failure and neprilysin inhibition","volume":"35","author":"Haynes","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2022.175053_bib17","first-page":"760","article-title":"[Chinese guidelines for the diagnosis and treatment of heart failure 2018]","volume":"46","year":"2018","journal-title":"Zhonghua Xinxueguanbing Zazhi"},{"key":"10.1016\/j.ejphar.2022.175053_bib18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jama.2010.39","article-title":"Alberta Kidney Disease, N. Relation between kidney function, proteinuria, and adverse outcomes","volume":"303","author":"Hemmelgarn","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2022.175053_bib19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/brain\/awt308","article-title":"Sustained peripheral depletion of amyloid-beta with a novel form of neprilysin does not affect central levels of amyloid-beta","volume":"137","author":"Henderson","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2022.175053_bib20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cardfail.2007.03.011","article-title":"High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database","volume":"13","author":"Heywood","year":"2007","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ejphar.2022.175053_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease - a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2022.175053_bib22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1042\/cs0770643","article-title":"Effect of alpha-human atrial natriuretic peptide on proteinuria in patients with primary glomerular diseases","volume":"77","author":"Ishi","year":"1989","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ejphar.2022.175053_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2362.1999.00422.x","article-title":"Atrial natriuretic peptide increases albuminuria in type I diabetic patients: evidence for blockade of tubular protein reabsorption","volume":"29","author":"Jacobs","year":"1999","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2022.175053_bib24","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1681\/ASN.2006010063","article-title":"Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction","volume":"17","author":"Jose","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2022.175053_bib25","first-page":"F936","article-title":"Effects of atrial natriuretic peptide on renal arterioles: morphometric analysis using microvascular casts","volume":"259","author":"Kimura","year":"1990","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2022.175053_bib26","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1161\/01.HYP.35.4.971","article-title":"Effects of cardiac natriuretic peptides on oxidized low-density lipoprotein- and lysophosphatidylcholine-induced human mesangial cell migration","volume":"35","author":"Kohno","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2022.175053_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2022.175053_bib28","first-page":"F1102","article-title":"Effects of atriopeptin III on isolated rat afferent and efferent arterioles","volume":"261","author":"Lanese","year":"1991","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2022.175053_bib29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Chronic Kidney Disease Epidemiology, C.Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2022.175053_bib30","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/ki.1997.396","article-title":"Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failure","volume":"52","author":"Lipkin","year":"1997","journal-title":"Kidney Int."},{"issue":"Suppl. 4","key":"10.1016\/j.ejphar.2022.175053_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2165\/00003495-199000394-00004","article-title":"Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function","volume":"39","author":"Ljungman","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2022.175053_bib32","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0006-291X(90)90744-8","article-title":"Atrial natriuretic peptide regulation of endothelial permeability is mediated by cGMP","volume":"172","author":"Lofton","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2022.175053_bib33","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0022-3565(25)22094-8","article-title":"Atrial natriuretic peptide reverses afferent arteriolar vasoconstriction and potentiates efferent arteriolar vasoconstriction in the isolated perfused rat kidney","volume":"246","author":"Loutzenhiser","year":"1988","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2022.175053_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/ndt\/gfw396","article-title":"Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection","volume":"33","author":"Mafham","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2022.175053_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/324473a0","article-title":"Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney","volume":"324","author":"Marin-Grez","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2022.175053_bib36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ehf2.12258","article-title":"Insights into implementation of sacubitril\/valsartan into clinical practice","volume":"5","author":"Martens","year":"2018","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ejphar.2022.175053_bib37","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/00004872-198810000-00003","article-title":"The effect of atrial natriuretic factor on urinary albumin and beta 2-microglobulin excretion in man","volume":"6","author":"McMurray","year":"1988","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2022.175053_bib38","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.175053_bib39","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1517\/14656566.2015.1000300","article-title":"LCZ696 : a new paradigm for the treatment of heart failure?","volume":"16","author":"Minguet","year":"2015","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2022.175053_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11845-007-0030-1","article-title":"Atrial natriuretic peptide increases urinary albumin excretion in people with normoalbuminuric type-2 diabetes","volume":"176","author":"Moore","year":"2007","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.ejphar.2022.175053_bib41","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s11739-019-02028-0","article-title":"Is echocardiography mandatory for patients with chronic kidney disease?","volume":"14","author":"Nardi","year":"2019","journal-title":"Int. Emerg. Med."},{"key":"10.1016\/j.ejphar.2022.175053_bib42","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ejhf.1342","article-title":"Effects of sacubitril\/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study","volume":"21","author":"Nougue","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2022.175053_bib43","first-page":"F415","article-title":"Direct vasodilatory action of atrial natriuretic factor on canine glomerular afferent arterioles","volume":"255","author":"Ohishi","year":"1988","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2022.175053_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000045836","article-title":"C-Type natriuretic peptide inhibits proliferation and monocyte chemoattractant protein-1 secretion in cultured human mesangial cells","volume":"86","author":"Osawa","year":"2000","journal-title":"Nephron"},{"key":"10.1016\/j.ejphar.2022.175053_bib45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejphar.2022.175053_bib46","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1681\/ASN.2012020145","article-title":"Chronic renal insufficiency cohort study, G.associations between kidney function and subclinical cardiac abnormalities in CKD","volume":"23","author":"Park","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2022.175053_bib47","first-page":"R1457","article-title":"Renal and vascular effects of C-type and atrial natriuretic peptides in humans","volume":"273","author":"Pham","year":"1997","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2022.175053_bib48","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.175053_bib49","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/(SICI)1096-9136(199808)15:8<678::AID-DIA639>3.0.CO;2-K","article-title":"Atrial natriuretic peptide increases urinary albumin excretion in men with type 1 diabetes mellitus and established microalbuminuria","volume":"15","author":"Prasad","year":"1998","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejphar.2022.175053_bib50","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1042\/CS20160197","article-title":"Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone","volume":"130","author":"Roksnoer","year":"2016","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ejphar.2022.175053_bib51","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1681\/ASN.2012040390","article-title":"Mechanisms and treatment of CKD","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2022.175053_bib52","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/ejhf.267","article-title":"Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?","volume":"17","author":"Ruggenenti","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2022.175053_bib53","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.175053_bib54","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrneph.2016.113","article-title":"Heart failure and kidney dysfunction: epidemiology, mechanisms and management","volume":"12","author":"Schefold","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejphar.2022.175053_bib55","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/PL00005140","article-title":"C-type natriuretic peptide inhibits rat mesangial cell proliferation by a phosphorylation-dependent mechanism","volume":"357","author":"Segawa","year":"1998","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175053_bib56","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/ejhf.603","article-title":"Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis","volume":"18","author":"Solomon","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2022.175053_bib57","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.175053_bib58","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.175053_bib59","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/ehf2.13002","article-title":"Effect of sacubitril\/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Spannella","year":"2020","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ejphar.2022.175053_bib60","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2022.175053_bib61","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00004872-199816020-00016","article-title":"Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers","volume":"16","author":"Vervoort","year":"1998","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2022.175053_bib62","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/ajkd.2002.33907","article-title":"Atrial natriuretic peptide-induced microalbuminuria is associated with endothelial dysfunction in noncomplicated type 1 diabetes patients","volume":"40","author":"Vervoort","year":"2002","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2022.175053_bib63","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction","volume":"17","author":"Voors","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2022.175053_bib64","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0140-6736(96)07424-7","article-title":"The natriuretic-peptide family","volume":"349","author":"Wilkins","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.175053_bib65","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/CIRCULATIONAHA.110.011031","article-title":"Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction","volume":"124","author":"Zile","year":"2011","journal-title":"Circulation"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922003144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922003144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:18:20Z","timestamp":1762143500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922003144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":65,"alternative-id":["S0014299922003144"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175053","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Sacubitril\/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175053"}}